Charles Schwab Trust’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.2M Hold
1,832
0.12% 75
2026
Q1
$1.68M Buy
1,832
+864
+89% +$876K 0.11% 76
2025
Q4
$1.04M Sell
968
-284
-23% -$272K 0.07% 90
2025
Q3
$956K Buy
1,252
+754
+151% +$561K 0.06% 92
2025
Q2
$388K Buy
498
+45
+10% +$35K 0.03% 137
2025
Q1
$374K Buy
453
+132
+41% +$110K 0.03% 128
2024
Q4
$248K Buy
321
+95
+42% +$78.7K 0.02% 147
2024
Q3
$200K Sell
226
-63
-22% -$56.6K 0.02% 150
2024
Q2
$262K Buy
+289
New +$231K 0.02% 137
2024
Q1
Sell
-833
Closed -$486K 165
2023
Q4
$486K Sell
833
-431
-34% -$252K 0.05% 119
2023
Q3
$679K Buy
1,264
+507
+67% +$261K 0.08% 106
2023
Q2
$325K Buy
757
+45
+6% +$18.9K 0.04% 116
2023
Q1
$245K Buy
+712
New +$240K 0.03% 130

Other funds holding LLY

Charles Schwab Trust's LLY Position: Q2 2026 in Review

Charles Schwab Trust held its Eli Lilly (LLY) position steady in Q2 2026 at 1,832 shares worth $2.2M. The position accounts for 0.12% of the portfolio, ranked #75.

Charles Schwab Trust first reported a position in LLY in Q1 2023 and has held it in 13 quarters since. 2,206 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Charles Schwab Trust held 1,832 shares of Eli Lilly worth $2.2M as of Q2 2026.
  • Charles Schwab Trust left its Eli Lilly share count unchanged in Q2 2026.
  • Eli Lilly made up 0.12% of Charles Schwab Trust's portfolio in Q2 2026, its #75 holding.
  • Charles Schwab Trust first reported a position in Eli Lilly in Q1 2023 and has held it in 13 quarters since.
  • 2,206 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Charles Schwab Trust's 13F filing for Q2 2026, filed 10 Jul 2026.